- Citations, last 5 years
- 150
- Works, last 5 years
- 27
- h-index
- 16
- Scientists listed
- 2
- Grants since 2016
- 3
Grants received
2022–2026 · research · R01
A Phase II/III randomized, placebo controlled, double blind study to evaluate the effects of up to 24 weeks of low dose pazopanib on HHT related epistaxis and anemia. IND#144808 June 25, 2020
James Richard Gossage · Cure HHT · funded by U.S. Food and Drug Administration
2022–2027 · research · R01
A Phase II/III randomized, placebo controlled, double blind study to evaluate the effects of up to 24 weeks of low dose pazopanib on HHT related epistaxis and anemia. IND#144808 June 25, 2020
James Richard Gossage · Cure HHT · funded by U.S. Food and Drug Administration
2022–2026 · research · R01
A Phase II/III randomized, placebo controlled, double blind study to evaluate the effects of up to 24 weeks of low dose pazopanib on HHT related epistaxis and anemia. IND#144808 June 25, 2020
James Richard Gossage · Cure HHT · funded by U.S. Food and Drug Administration